Professional APCs, epithelial cells, vascular endothelium, and tumor cells all express indoleamine-2,3-dioxygenase (IDO), an intracellular enzyme that catalyzes the first and rate-limiting step in the degradation pathway of the essential amino acid tryptophan. IDO is a crucial enzyme in the initiation and spread of cancer. It encourages tumor angiogenesis, immune tolerance to tumor antigens in stromal and immune cells, suppression of T and NK cells, production and activation of T regulatory cells (Tregs), and myeloid-derived suppressor cells. It also supports inflammation in the tumor microenvironment.According to reports, functionally active IDO protein is expressed in a wide range of human hematologic malignancies, including breast cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma, gynecological cancers, head and neck cancers, non-small cell lung cancer (NSCLC), melanoma, and pancreatic cancer. The IDO pathway is emerging as a crucial method for the treatment of cancer as an immune checkpoint pathway.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2811 | 8-Nitrotryptanthrin | 77603-42-0 | 8-Nitrotryptanthrin is a potent selective inhibitor of the human indoleamine 2,3-dioxygenase 2 (hIDO2) which dramatically reduces IDO2 activity with Kivalue of 0.97 μM. |
|
V3269 | BMS-986205 | 1923833-60-6 | Linrodostat (formerly known as BMS-986205, ONO-7701 and F001287) is a novel, potent, orally bioactive and selective inhibitor of IDO (indoleamine 2,3-dioxygenase 1) with potential anticancer activities. |
|
V0942 | Epacadostat (INCB024360) | 1204669-58-8 | Epacadostat (formerly INCB024360;IDO-IN-1;INCB-024360; INCB-24360; INCB24360) is an orally bioavailable, potent and selective IDO1(indoleamine-(2,3)-dioxygenase) inhibitor with potential immunomodulating and antitumor activity. |
|
V22433 | IDO-IN-1 | 914638-30-5 | IDO-IN-1 is a potent and selective indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM. |
|
V3146 | IDO-IN-2 | 1668565-74-9 | IDO inhibitor 1 (IDO-IN-2) is a novel and potent small molecule inhibitor of theIDO enzyme (indoleamine-(2,3)-dioxygenase)with an IC50 of 3 nM in cell free assays, and IC50values of 0.068 μM in HeLa cell and 0.16 μM in HEK293 cell. |
|
V0940 | INCB024360 analogue | 914471-09-3 | INCB024360 analog (Epacadostat analog; INCB-024360 analog; IDO-IN-2), a hydroxyamidine-based compound, is an orally bioavailable and competitive inhibitor of IDO1 (indoleamine-(2,3)-dioxygenase) with potential immunomodulating and anticancer activities. |
|
V0941 | Indoximod (NLG 8189) | 110117-83-4 | Indoximod (1-Methyl-D-tryptophan) is an orally bioactive indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. |
|
V24280 | LM10 | 1316695-35-8 | LM10 is a novel, potent and selective inhibitor of tryptophan 2,3-dioxygenase (TDO) with IC50 values of 0.62 and 2 μM for human and mouse TDO, respectively. |
|
V4880 | LY3381916 (IDO1-IN-5) | 2166616-75-5 | LY-3381916 (LY3381916) is a novel, potent, oral, selective and brain penetrant inhibitor ofIDO1 with anticancer activity. |
|
V3268 | Navoximod | 1402837-78-8 | Navoximod (formerly known as IDO-IN-7; NLG-1488; NLG919) is a potentinhibitor of the IDO(indoleamine-(2,3)-dioxygenase) pathway (Ki/EC50 = 7 nM/75 nM) with potential immunomodulating and antineoplastic activities. |
|
V0939 | NLG919 | 1402836-58-1 | NLG919 analog (RG6078 analog; GDC-0919 analog; GDC0919 analog; IDO-IN-7; NLG-919 analog) is a novel, potent and orally bioavailable inhibitor of IDO (indoleamine-(2,3)-dioxygenase) pathway with potential immunomodulating and antitumor activity. |
|
V3270 | PF-06840003 | 198474-05-4 | PF-06840003 (also known as PF06840003; EOS200271) is a highly potent and selective, orally bioavailableIDO-1inhibitor (IC50 of 0.15 μM) with anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
